Curcumin Modestly Lowers HOMA-IR in Overweight Adults; Other Compounds Show Little Effect
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Nichele S, Prates LM, Busetto L
Nov 14, 2026 · Published in: Nutrients
Curcumin may help combat insulin resistance in obesity.
Oral Orforglipron Weight Loss Across Six Trials: Efficacy, GI Tolerability, Gaps
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Paredes Yacaman GJ, Jiménez López AM, Cordova PR, et al.
Nov 11, 2026 · Published in: Cureus
Oral orforglipron shows promise for significant weight reduction.
Retatrutide Versus Tirzepatide in T2DM: Indirect Network Meta-Analysis of Sparse Data
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Tereshchenko A, Garay Gálvez B, Tello JA
Nov 10, 2026 · Published in: Therapeutic Advances in Endocrinology and Metabolism
Retatrutide outperforms in weight reduction for diabetes management.
Orforglipron Improves Physical Function More Reliably Than Psychosocial Measures in ATTAIN Trials
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Look M, Bays H, Le Roux CW, et al.
Nov 8, 2026 · Published in: Obesity Pillars
Orforglipron boosts physical and psychosocial health in obesity.
Win Statistics Reanalysis Favors Early Metformin in Gestational Diabetes, Driven by Insulin Avoidance
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Aguilar Macías DA, Alvarez-Iglesias A, Ferguson JM, et al.
Nov 3, 2026 · Published in: JAMA Network Open
Early metformin shows promise for gestational diabetes control.
Intranasal Insulin and Postoperative Delirium in Diabetes: Exploratory Subgroup Signal
Analysis Perioperative / Anesthesia Hypothesis-generating Grade: Very Low
Geng D, Ruan X, Yang H, et al.
Oct 28, 2026 · Published in: Aging Clinical and Experimental Research
Also in Geriatrics, Endocrinology / Diabetes / Obesity
Can intranasal insulin protect against postoperative delirium in older patients?
CagriSema Adds About 7 Points of Weight Loss Over Semaglutide 2.4 mg
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Oct 17, 2026 · Published in: Frontiers in Endocrinology
CagriSema offers superior weight loss over semaglutide alone.
Narrative Review Maps Incretin Obesity Therapy: Efficacy Hierarchy, Safety, and Pipeline Agents
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Oct 17, 2026 · Published in: Cureus
GLP-1 and GIP agonists redefine obesity treatment possibilities.
Oral Obesity Drugs Across CKM Stages: Only Semaglutide Has Outcomes Data
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Alhazmi A, Le Roux CW
Oct 14, 2026 · Published in: Drug Design, Development and Therapy
Also in Cardiology, Nephrology
Oral obesity drugs may redefine CKM syndrome treatment.
Pharmacist Obesity Care Shows Weight Benefits but Equity Evidence Remains Thin
Analysis Ambulatory Care / MTM Hypothesis-generating Grade: Low
Sharif FV, Sharif NV, Sharif Z
Oct 12, 2026 · Published in: Exploratory Research in Clinical and Social Pharmacy
Also in Endocrinology / Diabetes / Obesity
Do pharmacy interventions help reduce obesity and its inequities?
Semaglutide Plus Dapagliflozin: Short-Term Gains in Diabetic CKD
Analysis Nephrology Hypothesis-generating Grade: Very Low
Gong C, Luo Q, Li Q
Oct 9, 2026 · Published in: Medicine
Also in Endocrinology / Diabetes / Obesity
Could combining semaglutide and dapagliflozin benefit diabetic patients with kidney disease?
Prior GLP-1 Agonist Use Linked to Lower Post-Sepsis Mortality
Analysis Critical Care / ICU Hypothesis-generating Grade: Low
Liu HH, Huang SC, Wu JY, et al.
Oct 4, 2026 · Published in: Drug Design, Development and Therapy
Also in Endocrinology / Diabetes / Obesity
GLP-1 agonists may enhance survival in sepsis for type 2 diabetes patients.
Once-weekly efsitora shows hospitalization outcomes similar to daily basal insulin
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Philis-Tsimikas A, Galindo RJ, Guerci B, et al.
Oct 3, 2026 · Published in: Diabetes Research and Clinical Practice
Once-weekly insulin shows promising hospitalization outcomes in type 2 diabetes.
SGLT2 Inhibitors in Diabetic CKD: Metabolic Wins, Neutral Surrogates
Analysis Nephrology Confirmatory Grade: Moderate
Shi X, Fu K, Hu M, et al.
Oct 2, 2026 · Published in: Medicine
Also in Endocrinology / Diabetes / Obesity
SGLT2 inhibitors offer metabolic benefits but risk volume depletion in diabetic CKD.
Hybrid Closed-Loop Therapy Raises Time in Range 10 Points in Preschoolers
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Zhang T, Wang N, Wang B, et al.
Sep 30, 2026 · Published in: Pediatric Diabetes
Also in Pediatrics
Hybrid closed-loop systems enhance pediatric diabetes control safely.